Follow the people · Insider
Fairmount Funds Management LLC
Fairmount Funds Management LLC files insider transactions with the SEC as a director of Apogee Therapeutics (APGE). We hold 8 disclosed purchases and sales filed since 8 July 2020, 3 of them in the last 90 days.
- Files forAPGE
- Disclosed buys and sells8 in all, 3 in the last 90 days
- Last disclosure3 September 2026
Positions held
12 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 July 2023 — 3 September 2026Director · Apogee Therapeutics (APGE)21 Form 4 lines · source: SEC Form 4
- Filed 2 June 2026 — 16 July 2026Director and 10% owner · Crescent Biopharma (CBIO)3 Form 4 lines · source: SEC Form 4
- Filed 2 June 2026 — 1 July 2026Director and 10% owner · Oruka Therapeutics (ORKA)4 Form 4 lines · source: SEC Form 4
- Filed 27 May 2026 — 23 June 2026Director · Spyre Therapeutics (SYRE)4 Form 4 lines · source: SEC Form 4
- Filed 9 June 2026 — 9 June 2026Director and 10% owner · Jade Biosciences (JBIO)1 Form 4 line · source: SEC Form 4
- Filed 9 June 2025 — 11 May 2026Director and 10% owner · Viridian Therapeutics, Inc.\DE (VRDN)5 Form 4 lines · source: SEC Form 4
- Filed 16 June 2022 — 31 March 2026Director · Cogent Biosciences (COGT)19 Form 4 lines · source: SEC Form 4
- Filed 12 September 2024 — 31 March 2026Director · Zenas BioPharma (ZBIO)11 Form 4 lines · source: SEC Form 4
- Filed 23 March 2026 — 23 March 2026Director and 10% owner · Damora Therapeutics (DMRA)1 Form 4 line · source: SEC Form 4
- Filed 9 February 2026 — 9 February 2026Director and 10% owner · Galecto (GLTO)4 Form 4 lines · source: SEC Form 4
- Filed 22 January 2024 — 23 May 2024Director · Dianthus Therapeutics, Inc. /DE/ (DNTH)3 Form 4 lines · source: SEC Form 4
- Filed 6 July 2020 — 9 July 202010% owner · Unum Therapeutics (UMRX)6 Form 4 lines · source: SEC Form 4
Everything they disclosed
82 entries, newest first — one per disclosure report, one per Form 4 line- returned to the issuer 340,855 shares of Apogee TherapeuticsSEC Form 43 September 2026Common Stock · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 51,166 shares of Apogee TherapeuticsSEC Form 43 September 2026Common Stock · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 51,166 shares of Apogee TherapeuticsSEC Form 43 September 2026Common Stock · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 6,743,321 shares of Apogee Therapeutics (a derivative holding)SEC Form 43 September 2026Non-Voting Common Stock · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 47,758 shares of Apogee Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 10,370 shares of Apogee Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 14,461 shares of Apogee Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 3 September 2026 · filed 3 September 2026
- returned to the issuer 7,657 shares of Apogee Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 3 September 2026 · filed 3 September 2026
- exercised options over 31,838 shares of Apogee TherapeuticsSEC Form 411 August 2026Common Stock · traded 7 August 2026 · filed 11 August 2026
- exercised options over 10,370 shares of Apogee TherapeuticsSEC Form 411 August 2026Common Stock · traded 7 August 2026 · filed 11 August 2026
- exercised options over 31,838 shares of Apogee Therapeutics (a derivative holding)SEC Form 411 August 2026Stock Option (Right to Buy) · traded 7 August 2026 · filed 11 August 2026
- exercised options over 10,370 shares of Apogee Therapeutics (a derivative holding)SEC Form 411 August 2026Stock Option (Right to Buy) · traded 7 August 2026 · filed 11 August 2026
- ▲ bought on the open market 853,450 shares of Crescent BiopharmaSEC Form 420 July 2026Ordinary Shares · traded 16 July 2026 · filed 20 July 2026
- ▲ bought on the open market 525,897 shares of Crescent Biopharma (a derivative holding)SEC Form 420 July 2026Pre-Funded Warrant (Right to Buy) · traded 16 July 2026 · filed 20 July 2026
- converted 3,553,410 shares of Oruka TherapeuticsSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 3,553,410 shares of Oruka TherapeuticsSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- converted 42,641 shares of Oruka Therapeutics (a derivative holding)SEC Form 41 July 2026Series B Preferred Stock · traded 1 July 2026 · filed 1 July 2026
- converted 666,680 shares of Spyre TherapeuticsSEC Form 423 June 2026Common Stock · traded 23 June 2026 · filed 23 June 2026
- ▼ sold on the open market 4,684,781 shares of Spyre TherapeuticsSEC Form 423 June 2026Common Stock · traded 23 June 2026 · filed 23 June 2026
- converted 16,667 shares of Spyre Therapeutics (a derivative holding)SEC Form 423 June 2026Series B Preferred Stock · traded 23 June 2026 · filed 23 June 2026
- was granted 7,657 shares of Apogee Therapeutics (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 9 June 2026 · filed 11 June 2026
- was granted 34,843 shares of Jade Biosciences (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 9 June 2026 · filed 11 June 2026
- was granted 9,136 shares of Oruka Therapeutics (a derivative holding)SEC Form 43 June 2026Stock Option (Right to Buy) · traded 2 June 2026 · filed 3 June 2026
- was granted 11,050 shares of Crescent Biopharma (a derivative holding)SEC Form 43 June 2026Stock Option (Right to Buy) · traded 2 June 2026 · filed 3 June 2026
- was granted 8,026 shares of Spyre Therapeutics (a derivative holding)SEC Form 429 May 2026Stock Option (Right to Buy) · traded 27 May 2026 · filed 29 May 2026
- ▲ bought on the open market 1,176,470 shares of Viridian Therapeutics, Inc.\DESEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- ▲ bought on the open market 150,000 shares of Zenas BioPharmaSEC Form 41 April 2026Common Stock · traded 31 March 2026 · filed 1 April 2026
- converted 7,000,000 shares of Cogent BiosciencesSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- ▼ sold on the open market 7,000,000 shares of Cogent BiosciencesSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- converted 28,000 shares of Cogent Biosciences (a derivative holding)SEC Form 431 March 2026Series A Convertible Preferred Stock · traded 31 March 2026 · filed 31 March 2026
- converted 28,000 shares of Cogent Biosciences (a derivative holding)SEC Form 431 March 2026Series A Convertible Preferred Stock · traded 31 March 2026 · filed 31 March 2026
- converted 7,000,000 shares of Cogent BiosciencesSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- ▼ sold on the open market 7,000,000 shares of Cogent BiosciencesSEC Form 431 March 2026Common Stock · traded 31 March 2026 · filed 31 March 2026
- was granted 37,313 shares of Damora Therapeutics (a derivative holding)SEC Form 425 March 2026Stock Option (right to buy) · traded 23 March 2026 · filed 25 March 2026
- exercised options over 5,809,000 shares of GalectoSEC Form 412 February 2026Common Stock · traded 9 February 2026 · filed 12 February 2026
- exercised options over 2,904,000 shares of GalectoSEC Form 412 February 2026Common Stock · traded 9 February 2026 · filed 12 February 2026
- exercised options over 5,809 shares of Galecto (a derivative holding)SEC Form 412 February 2026Series C Preferred Stock · traded 9 February 2026 · filed 12 February 2026
- exercised options over 2,904 shares of Galecto (a derivative holding)SEC Form 412 February 2026Series C Preferred Stock · traded 9 February 2026 · filed 12 February 2026
- ▼ sold on the open market 1,750,000 shares of Apogee TherapeuticsSEC Form 422 January 2026Common Stock · traded 22 January 2026 · filed 22 January 2026
- ▼ sold on the open market 3,500,000 shares of Cogent BiosciencesSEC Form 422 January 2026Common Stock · traded 22 January 2026 · filed 22 January 2026
- ▼ sold on the open market 3,500,000 shares of Cogent BiosciencesSEC Form 422 January 2026Common Stock · traded 22 January 2026 · filed 22 January 2026
- ▲ bought on the open market 2,777,777 shares of Cogent BiosciencesSEC Form 414 July 2025Common Stock · traded 10 July 2025 · filed 14 July 2025
- was granted 14,461 shares of Apogee Therapeutics (a derivative holding)SEC Form 420 June 2025Stock Option (Right to Buy) · traded 17 June 2025 · filed 20 June 2025
- was granted 14,461 shares of Apogee Therapeutics (a derivative holding)SEC Form 420 June 2025Stock Option (Right to Buy) · traded 17 June 2025 · filed 20 June 2025
- exercised options over 1,600 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 411 June 2025Stock Option (Right to Buy) · traded 9 June 2025 · filed 11 June 2025
- exercised options over 12,500 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 411 June 2025Stock Option (Right to Buy) · traded 10 June 2025 · filed 11 June 2025
- exercised options over 1,600 shares of Viridian Therapeutics, Inc.\DESEC Form 411 June 2025Common Stock · traded 9 June 2025 · filed 11 June 2025
- exercised options over 12,500 shares of Viridian Therapeutics, Inc.\DESEC Form 411 June 2025Common Stock · traded 10 June 2025 · filed 11 June 2025
- converted 357,143 shares of Zenas BioPharma (a derivative holding)SEC Form 417 September 2024Series Seed Convertible Preferred Stock · traded 16 September 2024 · filed 17 September 2024
- converted 2,195,871 shares of Zenas BioPharma (a derivative holding)SEC Form 417 September 2024Series A Convertible Preferred Stock · traded 16 September 2024 · filed 17 September 2024
- converted 6,163,236 shares of Zenas BioPharma (a derivative holding)SEC Form 417 September 2024Series B Convertible Preferred Stock · traded 16 September 2024 · filed 17 September 2024
- converted 2,614,287 shares of Zenas BioPharma (a derivative holding)SEC Form 417 September 2024Series C Convertible Preferred Stock · traded 16 September 2024 · filed 17 September 2024
- was granted 37,000 shares of Zenas BioPharma (a derivative holding)SEC Form 417 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 17 September 2024
- converted 41,130 shares of Zenas BioPharmaSEC Form 417 September 2024Common Stock · traded 16 September 2024 · filed 17 September 2024
- converted 252,890 shares of Zenas BioPharmaSEC Form 417 September 2024Common Stock · traded 16 September 2024 · filed 17 September 2024
- converted 709,794 shares of Zenas BioPharmaSEC Form 417 September 2024Common Stock · traded 16 September 2024 · filed 17 September 2024
- converted 301,077 shares of Zenas BioPharmaSEC Form 417 September 2024Common Stock · traded 16 September 2024 · filed 17 September 2024
- ▲ bought on the open market 300,000 shares of Zenas BioPharmaSEC Form 417 September 2024Common Stock · traded 16 September 2024 · filed 17 September 2024
- exercised options over 1,500 shares of Cogent Biosciences (a derivative holding)SEC Form 412 June 2024Series B Convertible Preferred Stock · traded 10 June 2024 · filed 12 June 2024
- exercised options over 1,500,000 shares of Cogent BiosciencesSEC Form 412 June 2024Common Stock · traded 10 June 2024 · filed 12 June 2024
- was granted 11,000 shares of Dianthus Therapeutics, Inc. /DE/ (a derivative holding)SEC Form 428 May 2024Stock Option (Right to Buy) · traded 23 May 2024 · filed 28 May 2024
- acquired or disposed of, other 11,914 shares of Cogent Biosciences (a derivative holding)SEC Form 41 April 2024Series A Convertible Preferred Stock · traded 28 March 2024 · filed 1 April 2024
- acquired or disposed of, other 11,914 shares of Cogent Biosciences (a derivative holding)SEC Form 41 April 2024Series A Convertible Preferred Stock · traded 28 March 2024 · filed 1 April 2024
- acquired or disposed of, other 286,851 shares of Cogent BiosciencesSEC Form 41 April 2024Common Stock · traded 28 March 2024 · filed 1 April 2024
- acquired or disposed of, other 286,851 shares of Cogent BiosciencesSEC Form 41 April 2024Common Stock · traded 28 March 2024 · filed 1 April 2024
- was granted 1,500 shares of Cogent Biosciences (a derivative holding)SEC Form 416 February 2024Series B Convertible Preferred Stock · traded 16 February 2024 · filed 16 February 2024
- was granted 1,166,666 shares of Cogent BiosciencesSEC Form 416 February 2024Common Stock · traded 16 February 2024 · filed 16 February 2024
- was granted 832,333 shares of Dianthus Therapeutics, Inc. /DE/ (a derivative holding)SEC Form 424 January 2024Pre-Funded Warrants (Right to Buy) · traded 22 January 2024 · filed 24 January 2024
- was granted 834,334 shares of Dianthus Therapeutics, Inc. /DE/SEC Form 424 January 2024Common Stock · traded 22 January 2024 · filed 24 January 2024
- was granted 47,758 shares of Apogee Therapeutics (a derivative holding)SEC Form 417 July 2023Stock Option (Right to Buy) · traded 13 July 2023 · filed 17 July 2023
- was granted 47,758 shares of Apogee Therapeutics (a derivative holding)SEC Form 417 July 2023Stock Option (Right to Buy) · traded 13 July 2023 · filed 17 July 2023
- ▲ bought on the open market 55,913 shares of Apogee TherapeuticsSEC Form 417 July 2023Common Stock · traded 13 July 2023 · filed 17 July 2023
- ▲ bought on the open market 1,992,734 shares of Apogee TherapeuticsSEC Form 417 July 2023Common Stock · traded 13 July 2023 · filed 17 July 2023
- ▲ bought on the open market 892,529 shares of Apogee TherapeuticsSEC Form 417 July 2023Common Stock · traded 13 July 2023 · filed 17 July 2023
- ▲ bought on the open market 800,000 shares of Cogent BiosciencesSEC Form 413 June 2023Common Stock · traded 9 June 2023 · filed 13 June 2023
- ▲ bought on the open market 1,200,000 shares of Cogent BiosciencesSEC Form 421 June 2022Common Stock · traded 16 June 2022 · filed 21 June 2022
- ▲ bought on the open market 3,692 shares of Unum Therapeutics (a derivative holding)SEC Form 413 July 2020Series A Convertible Preferred Stock · traded 9 July 2020 · filed 13 July 2020
- ▲ bought on the open market 19,035 shares of Unum Therapeutics (a derivative holding)SEC Form 413 July 2020Series A Convertible Preferred Stock · traded 9 July 2020 · filed 13 July 2020
- acquired or disposed of, other 8,222 shares of Unum Therapeutics (a derivative holding)SEC Form 48 July 2020Series A Convertible Preferred Stock · traded 6 July 2020 · filed 8 July 2020
- acquired or disposed of, other 36,465 shares of Unum Therapeutics (a derivative holding)SEC Form 48 July 2020Series A Convertible Preferred Stock · traded 6 July 2020 · filed 8 July 2020
- acquired or disposed of, other 1,147,406 shares of Unum TherapeuticsSEC Form 48 July 2020Common Stock · traded 6 July 2020 · filed 8 July 2020
- acquired or disposed of, other 5,088,497 shares of Unum TherapeuticsSEC Form 48 July 2020Common Stock · traded 6 July 2020 · filed 8 July 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.